Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DUR0F6
|
|||
| Drug Name |
SYNB1891
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-10: C81-C86; ICD-9: 202] | Phase 1 | [1] | |
| Neoplasm [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [1] | ||
| Company |
Symphogen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Stimulator of interferon genes protein (TMEM173) | Target Info | Agonist | [2] |
| KEGG Pathway | NOD-like receptor signaling pathway | |||
| RIG-I-like receptor signaling pathway | ||||
| Cytosolic DNA-sensing pathway | ||||
| Human cytomegalovirus infection | ||||
| Herpes simplex virus 1 infection | ||||
| Human immunodeficiency virus 1 infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04167137) Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020 Jun 1;11(1):2739. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.